Jiangsu Bioperfectus Technologies Co., Ltd.

Shanghai Stock Exchange 688399.SS

Jiangsu Bioperfectus Technologies Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 8.58

Jiangsu Bioperfectus Technologies Co., Ltd. Price to Sales Ratio (P/S) is 8.58 on January 14, 2025, a 9.93% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Jiangsu Bioperfectus Technologies Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 13.73 on October 08, 2024, which is 60.11% above the current Price to Sales Ratio (P/S).
Jiangsu Bioperfectus Technologies Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 7.35 on January 18, 2024, which is -14.33% below the current Price to Sales Ratio (P/S).
Jiangsu Bioperfectus Technologies Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 9.97.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shanghai Stock Exchange: 688399.SS

Jiangsu Bioperfectus Technologies Co., Ltd.

CEO	Dr. Guoqiang Wang
IPO Date	Dec. 5, 2019
Location	China
Headquarters	Block G19 1
Employees	684
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Jiangsu Bioperfectus Technologies Co., Ltd. researches and develops, produces, and sells in vitro diagnostic products in China. It offers in vitro diagnostic reagents and supporting detectors, as well as in vitro testing services. The company was founded in 2010 and is based in Taizhou, China.

Key trends

Past 5 years